Novo Nordisk releases low-dose CagriSema data as approval decision nears

The wire

1. 01Novo Nordisk disclosed data on a lower dose of investigational CagriSema, a cagrilintide plus semaglutide combination, during the second day of its capital markets day in London.
2. 02A lower-dose option would matter to prescribers and pharmacies weighing tolerability and titration against tirzepatide, and to operators planning stocking ahead of a regulatory decision.
3. 03Full trial details, comparators and the timing of the pending approval decision were not laid out in the company's disclosure; the data come from the sponsor, not a peer-reviewed publication.

From the source

Novo offers low-dose CagriSema data as approval decision looms

As its cap­i­tal mar­kets day in Lon­don con­tin­ued on Mon­day, No­vo re­leased da­ta that sug­gest­ed its in­ves­ti­ga­tion­al meta­bol­ic drug Ca­griSe­ma was com­pet­i­tive …